ProfileJobs (71)

Accuray

HealthManufacturing & Industrialmedical devicestherapy
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a radiation oncology company that manufactures and sells precise, leading-edge treatment solutions that revolve around the patient. Accuray's innovative technologies – the CyberKnife and TomoTherapy Systems – set the standard of care with the aim of helping patients live longer, better lives. For more information, please visit www.accuray.com.
Revenue(Q3, 2017)
$97.3 M
Market capitalization(2017-08-17)
$335.8 M
Company Growth (employees)
Type
Public
HQ
Sunnyvale, US
Size (employees)
959 (est)
Website
accuray.com
Accuray is headquartered in Sunnyvale, US

Accuray Office Locations

Accuray has offices in Sunnyvale, Morges, Madison, Chiyoda and in 5 other locations
Sunnyvale, US (HQ)
1310 Chesapeake Terrace
Chengdu, CN
#39 Huatai Road, Longtan Industrial Zone, Section 2 East, 3rd Ring Road
Hong Kong, HK
Suites 1702 - 1704, Tower 6 The Gateway, Harbour City 9 Canton Road, T.S.T.
Madison, US
1240 Deming Way
Morges, CH
9 Route de la Longeraie
Show all (9)

Accuray Data and Metrics

Accuray Financial Metrics

Accuray's revenue was reported to be $97.3 m in Q3, 2017
USD

Revenue (Q3, 2017)

97.3 m

Gross profit (Q3, 2017)

35.4 m

Gross profit margin (Q3, 2017), %

36%

Net income (Q3, 2017)

(5 m)

EBIT (Q3, 2017)

(1.3 m)

Market capitalization (17-Aug-2017)

335.8 m

Cash (31-Mar-2017)

60.2 m
Accuray's current market capitalization is $335.8 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

369.4 m379.8 m398.8 m

Revenue growth, %

3%5%

Cost of goods sold

226.6 m234.4 m240.1 m

Gross profit

142.8 m145.4 m158.7 m

Gross profit Margin, %

39%38%40%

R&D expense

56.7 m

General and administrative expense

50.1 m

Operating expense total

160.9 m164.6 m163.6 m

EBIT

(18.1 m)(19.2 m)(4.9 m)

EBIT margin, %

(5%)(5%)(1%)

Pre tax profit

(32.4 m)(37.8 m)(23.2 m)

Income tax expense

3.1 m2.4 m2.3 m

Net Income

(35.4 m)(40.2 m)(25.5 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

82.4 m98.2 m97.5 m89.6 m108.9 m105.3 m86.5 m87.5 m97.3 m

Cost of goods sold

54.6 m59.7 m58.9 m55.7 m66.3 m60.3 m55.2 m56.1 m61.9 m

Gross profit

27.8 m38.5 m38.7 m33.9 m42.6 m44.9 m31.3 m31.4 m35.4 m

Gross profit Margin, %

34%39%40%38%39%43%36%36%36%

R&D expense

14.1 m13.9 m12.8 m14.3 m14.9 m13.3 m12.2 m11.9 m12.5 m

General and administrative expense

11 m12.4 m11.7 m13.4 m12.7 m13.7 m11.3 m10.4 m11.2 m

Operating expense total

25.1 m26.3 m24.5 m27.7 m27.6 m27 m23.6 m22.3 m23.7 m

EBIT

(15.3 m)(3.6 m)1.2 m(7.2 m)(124 k)5.4 m(6.5 m)(4.8 m)(1.3 m)

EBIT margin, %

(19%)(4%)1%(8%)(0%)5%(8%)(6%)(1%)

Pre tax profit

(20.7 m)(9.1 m)(2.4 m)(12.3 m)(5.2 m)(10.6 m)(8.9 m)

Income tax expense

917 k873 k521 k704 k833 k723 k(626 k)426 k842 k

Net Income

(21.7 m)(10 m)(3 m)(13 m)(6 m)756 k(9.9 m)(9.4 m)(5 m)
USDFY, 2014FY, 2015FY, 2016

Cash

92.3 m79.6 m119.8 m

Inventories

87.8 m106.2 m116 m

Current Assets

364.5 m354.3 m361.7 m

PP&E

34.4 m31.8 m27.9 m

Goodwill

58.1 m58.1 m57.8 m

Total Assets

495.2 m470 m469 m

Accounts Payable

15.6 m13.1 m15.2 m

Total Debt

170.5 m

Current Liabilities

184.6 m169.9 m210.2 m

Total Liabilities

409.4 m

Additional Paid-in Capital

451.8 m471.4 m481.3 m

Retained Earnings

(355.1 m)(395.3 m)(420.8 m)

Total Equity

98.5 m75.8 m59.7 m

Debt to Equity Ratio

2.9 x

Debt to Assets Ratio

0.4 x

Financial Leverage

5 x6.2 x7.9 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

107.3 m97.3 m95.4 m85.6 m88.5 m79.2 m83.6 m69.5 m60.2 m

Inventories

100 m104.5 m109.7 m113.8 m111.5 m117.1 m117.4 m116.9 m116.6 m

Current Assets

335.8 m346.7 m348 m350.7 m358.3 m380.6 m318.8 m316.7 m310.3 m

PP&E

32.7 m30.8 m29.9 m29.5 m29.6 m29.1 m26.6 m25 m23.4 m

Goodwill

58.1 m58 m58 m58 m57.9 m57.9 m57.8 m57.7 m57.7 m

Total Assets

459.6 m467.6 m463.7 m461.8 m473.3 m490 m422.7 m415.2 m416.8 m

Accounts Payable

14.7 m16 m13.7 m13.7 m19.6 m21.7 m17 m25.2 m23.6 m

Current Liabilities

164.9 m172.1 m165.8 m263.3 m274.2 m229.6 m172.2 m179.8 m296.2 m

Additional Paid-in Capital

455.9 m462 m466 m473 m476.4 m476.2 m484.9 m488.9 m492.3 m

Retained Earnings

(376.7 m)(386.7 m)(389.7 m)(408.3 m)(414.4 m)(413.6 m)(430.7 m)(440.1 m)(445.1 m)

Total Equity

80.5 m75.9 m76.5 m64.1 m60.9 m62.3 m53.4 m46.7 m45.5 m

Financial Leverage

5.7 x6.2 x6.1 x7.2 x7.8 x7.9 x7.9 x8.9 x9.2 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(40.2 m)(25.5 m)

Depreciation and Amortization

20.6 m19.5 m18.3 m

Accounts Receivable

(15 m)(8.3 m)23 m

Inventories

(8.3 m)(21 m)(11 m)

Accounts Payable

(1.1 m)(1.8 m)2.4 m

Cash From Operating Activities

346 k(16.7 m)33.5 m

Cash From Investing Activities

8.5 m3.7 m8.3 m

Long-term Borrowings

(66.4 m)

Cash From Financing Activities

8.4 m5.9 m(757 k)

Interest Paid

8.2 m7.2 m10.3 m

Income Taxes Paid

2.5 m3.2 m1 m
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(21.7 m)(10 m)(3 m)(13 m)(6 m)756 k(9.9 m)(9.4 m)(5 m)

Inventories

100 m104.5 m109.7 m113.8 m111.5 m117.1 m117.4 m116.9 m116.6 m

Accounts Payable

14.7 m16 m13.7 m13.7 m19.6 m21.7 m17 m25.2 m23.6 m
USDY, 2017

Revenue/Employee

101.5 k

Financial Leverage

9.2 x

Accuray Market Value History

Accuray Job Categories

Market Position of Accuray

Competitors

Axonics Modulation Technologies
Health - Private
Relievant Medsystems
Health - Private
Cape Medical Supply
Health - Private
Luma Therapeutics
Health - Private
Compare competitors

Traffic Overview of Accuray

Accuray Online and Social Media Presence

Accuray News and Updates

June 27, 2016

BRIEF-Accuray receives 510(K) FDA clearance for image-guided radiation therapy

* Accuray receives 510(k) FDA clearance for the Radixact image-guided radiation therapy platform and integrated software

Accuray Company Life and Culture

You may also be interested in